toxylact: a03cb02 belladonna total alkaloids & psycholeptics
The first professional lActological database in the word
A03CB02 Belladonna total alkaloids and psycholeptics is an ATC subgroup covering belladonna-derived anticholinergic alkaloids used with psycholeptics, mainly in combinations for functional gastrointestinal disorders, and the referenced page notes belladonna’s narrow therapeutic window and toxic potential.medpedia.framar
Toxicological profile
Belladonna
contains tropane alkaloids,
especially atropine, and the therapeutic dose is close to
the toxic dose.medpedia.framar
Poisoning classically causes dry mouth, mydriasis, tremor,
hoarseness or loss
of voice, and other anticholinergic effects.medpedia.framar
The root is described on the page as the most poisonous
part of the plant.medpedia.framar
Lactation considerations
From
a lactological perspective, this class
should be treated as high caution during
breastfeeding because
atropine-like anticholinergic agents may reduce milk
production and can
potentially cause anticholinergic effects in the infant.
Use in lactation should be reserved for clear clinical
need, with preference
for the lowest effective dose and shortest duration, and
infant monitoring for
poor feeding, drowsiness, irritability, constipation, or
dehydration.
Because combination products may include psycholeptics,
the lactation risk can
be amplified by the sedative component.
Clinical use
The
class is used in combination products for
symptomatic treatment of functional gastrointestinal
disorders, where the
antispasmodic effect is paired with a calming or
psycholeptic action.medpedia.framar
The anticholinergic component reduces smooth-muscle spasm
and secretions, which
can help some cramp-related GI complaints.
However, because the safety margin is limited, these
products require careful
dose control and are unsuitable for casual
self-medication.
Safety notes
Overdose
risk is clinically important because
the therapeutic and toxic ranges are close.medpedia.framar
Caution is especially important in patients with glaucoma,
urinary retention,
prostatic hypertrophy, bowel obstruction,
tachyarrhythmias, or sensitivity to
anticholinergic drugs.
In breastfeeding patients, the combination with
psycholeptics warrants
additional caution due to possible infant sedation and
feeding difficulties.



